Core Viewpoint - The company announced a milestone payment of $5 million from its partner Caldera Therapeutics, triggered by the approval of QX030N/CLD-423 for human clinical trials by the Human Research Ethics Committee (HREC) [1] Group 1: Clinical Development - The dual antibody QX030N/CLD-423 has received HREC approval in Australia and is set to begin clinical trials in early 2026 [1] - The upcoming trial will be a randomized, double-blind, placebo-controlled, dose-escalation Phase I study aimed at evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) characteristics of QX030N/CLD-423 in healthy adults [1] Group 2: Strategic Implications - This approval marks the official entry of the company's dual antibody matrix into the clinical stage overseas, reinforcing its leading position in the fields of autoimmune and allergic diseases [1] - The company and Caldera will accelerate project development to achieve further clinical progress [1]
荃信生物-B(02509.HK)：”QX030N“于澳大利亚的I期临床试验获得人类研究伦理委员会许可及收到里程碑付款